title: [Prophylaxis of transitional cell carcinoma of the bladder G1-G2; pTa-pT1 with mitomycin C or interferon alpha-2a. Preliminary data].
abstract: No. 54 patients with transitional cell carcinoma G1-2; pTa-pT1, were treated with intravesical therapy with Mitomycin C (MMC) (first group of 27 patients), and Interferon alfa 2a (IFN) (second group of 27 patients), following transurethral resection. The objective of this trial was to compare the prophylactic activity of these two drugs. All patients were evaluated with cystoscopy and urine cytology. Mean follow-up was for the first group of patients (MMC) of 10.4 months, for the second group (IFN) of 12 months. The incidence of recurrence in the first group (MMC) was 11.1% with a recurrence rate of 2.1. In the second group (IFN) the incidence of recurrence was 51.9% with a recurrence rate of 7.4. No case of progression evaluated by grade and stage was observed. The side-effects were more frequent in the MMC group and they were mainly due to chemocystitis. These data suggest that MMC appears to be superior to IFN in intravesical therapy of superficial bladder carcinoma.
authors.affiliation: Divisione Urologia, Ospedale Civile di Jesi, Ancona.
authors.forename: C
authors.initials: C
authors.lastname: Vecchioli Scaldazza
mesh_terms: D002295:Carcinoma, Transitional Cell / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D016685:Mitomycin / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control*; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016685:Mitomycin
vernacular_title: La profilassi del carcinoma a cellule di transizione della vesicia G1-G2; pTa-pT1 con mitomycin C o interferone alpha-2a. Dati preliminari.